S2519 Statins and Cirrhosis Outcomes: Retrospective Study Shows Improved Fibroscore and Lower Readmissions

Introduction: Statins, known for cardiovascular benefits, may offer additional therapeutic effects. This study investigates their role in improving fibroscore—a marker of liver fibrosis—and reducing 30-day hospital readmissions in cirrhosis patients. Using retrospective data from 2021–2024, we analyzed the impact of atorvastatin on fibrosis progression and short-term outcomes. Findings aim to clarify the extended value of statin therapy in liver disease management and inform future clinical strategies. Methods: A retrospective analysis of inpatient hospital data, including all cirrhosis patients admitted from 2021 to 2024, was conducted. Patients were initially assessed for their pre-statin fibroscore, with only those ranging from F1 to F3 being selected for inclusion in the study. These patients were then administered 20 mg of atorvastatin and monitored over a year, during which post-statin fibroscores were recorded. The study aimed to evaluate the impact of statin use on fibroscore improvement after 1 year and to assess 30-day readmission rates. Categorical data concerning statin usage, changes in fibroscore, and hospital readmissions were analyzed. Chi-squared tests of independence were employed to explore significant relationships between statin use and the observed outcomes. Results: The study analyzed 150 patients, of whom 47% were on statins and 53% were not. Among statin patients, 35% showed improvement in fibroscore after 1 year, compared to 20% in the non-statin group, statistically significant (P = 0.025), indicating that statin use may strongly impact fibroscore improvement. Regarding 30-day readmission rates, only 10% of statin users were readmitted, significantly lower than the 35% readmission rate in the non-statin group. The association between statin use and reduced readmission was highly significant (P < 0.01). Conclusion: This study found a significant association between statin use and improved fibroscore, as well as reduced 30-day readmission rates. While statins are primarily used for lipid control in cardiovascular disease, they may also support liver health and stability, reducing complications and the need for acute care. This dual benefit is particularly valuable for patients with both cardiovascular and chronic liver diseases. These results suggest a broader role for statins in managing liver fibrosis and frequent hospitalizations, warranting further research on long-term benefits.